J. Royalty

发表

Investigation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of a Long-Acting α-MSH Analog in Healthy Overweight and Obese Subjects

B. Wulff, B. S. Hansen, J. Royalty, 2013, Journal of clinical pharmacology.

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

J. Suico, D. Small, J. Royalty, 2016, European Journal of Clinical Pharmacology.

Lack of Effect of Aprepitant on Hydrodolasetron Pharmacokinetics in CYP2D6 Extensive and Poor Metabolizers

P. Lupinacci, T. Rushmore, E. Pequignot, 2006, Journal of clinical pharmacology.

Effects of Aspirin When Added to the Prostaglandin D2 Receptor Antagonist Laropiprant on Niacin‐Induced Flushing Symptoms

F. Liu, J. Paolini, J. Wagner, 2009, Journal of clinical pharmacology.

Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects

J. Suico, D. Small, J. Royalty, 2016, Pharmacotherapy.

Safety, tolerability, and pharmacokinetic evaluation of single‐ and multiple‐ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects

S. Tauscher‐Wisniewski, L. Rorick-Kehn, G. Dickinson, 2014, Journal of clinical pharmacology.

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

J. Suico, D. Small, J. Royalty, 2016, European Journal of Clinical Pharmacology.

Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [13C8]‐evacetrapib as a tracer

J. Suico, B. Pack, K. Ruterbories, 2015, Journal of labelled compounds & radiopharmaceuticals.

Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer

P. Kulanthaivel, S. Hall, J. Rehmel, 2020, Drug Metabolism and Disposition.

A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State

J. Suico, S. Friedrich, D. Small, 2015, Journal of cardiovascular pharmacology and therapeutics.

Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate

J. Bonventre, P. Kulanthaivel, S. Hall, 2018, Clinical pharmacology and therapeutics.

Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy Subjects

O. Laterza, J. Wagner, J. Schwartz, 2008, Journal of clinical pharmacology.

Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects

J. Chodakewitz, W. Kraft, J. Wagner, 2010, Platelets.

Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers

J. Wagner, D. Ebel, G. Atiee, 2010, Journal of clinical pharmacology.

Quantitative cytocentrifugation in the evaluation of cerebrospinal fluid.

E. Whitmore, F. Hochberg, J. Royalty, 1982, Acta cytologica.

Pharmacokinetics and muscle distribution of AT2220, a pharmacological chaperone of acid-glucosidase, in healthy volunteers

S. Sitaraman, A. Bragat, P. Boudes, 2011 .